Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance

• ClinicalTrials.gov Identifier: NCT03579654
• Recruitment Status: Unknown
• First Posted: July 6, 2018
• Last Update Posted: March 6, 2019
• Sponsor: OncBioMune Pharmaceuticals
• Information provided by (Responsible Party): OncBioMune Pharmaceuticals

Study Description

Brief Summary:

This study will evaluate the safety and efficacy of a prostate cancer vaccine named Proscavax (Prostate-specific antigen(PSA) / Interleukin-2(IL-2) / Granulocyte-macrophage colony-stimulating factor(GM-CSF)) in patients with localized prostate cancer. The goal of the study is to determine if vaccine administration results in a change in the rate of prostate cancer progression when compared to a no-treatment control group of active surveillance patients.

The researchers are interested in evaluating the proportion of participants with prostate cancer progression at 2 years following administration of Proscavax or active surveillance, the effect of the vaccine on prostate-specific antigen (PSA) doubling time and the assessment of adverse events in these patients.

Eligible patients in this study will include men who are 18 years and older and who have a previously untreated early stage prostate cancer regardless of the date of diagnosis.

Condition or disease	Intervention/treatment	Phase
Prostate Cancer	Biological: Proscavax	Phase 2

Detailed Description:

This study will have 2 arms and patients will be randomized 2:1 into the Proscavax treatment arm (Arm 1) versus the active surveillance arm (Arm 2).

In study Arm 1, 6 doses of the vaccine will be administered intradermally at weeks 1, 2, 3, 7, 11, and 15, followed by maintenance booster injections once every month which will alternate between low dose IL-2 alone (at weeks 19, 27 and 35) and Proscavax vaccine (at weeks 23, 31, 39) for 6 months.

In study Arm 2, patients will undergo active surveillance and will not receive any Proscavax vaccine treatment.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 120 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2, Randomized Study of Proscavax, a PSA/IL-2/GM-CSF Vaccine, in Treatment-naive Patients With Clinically Localized Prostate Cancer Versus an Active Surveillance Strategy
• Estimated Study Start Date: February 28, 2019
• Estimated Primary Completion Date: February 28, 2021
• Estimated Study Completion Date: June 30, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm 1 - Proscavax vaccine treatment; In this arm, during the first 4 months of induction treatment, 6 doses of the Proscavax vaccine will be administered intradermally at weeks 1, 2, 3, 7, 11, and 15, followed by maintenance booster injections once every month which will alternate between low dose IL-2 alone (at weeks 19, 27 and 35) and Proscavax vaccine (at weeks 23, 31, 39) for 6 months.	Biological: Proscavax; Proscavax is a prostate cancer vaccine which combines the prostate antigen PSA with immune stimulatory cytokines (IL-2 and GM-CSF).
No Intervention: Arm 2 - Active Surveillance; In this arm, patients will undergo active surveillance and will not receive any Proscavax vaccine treatment.

Outcome Measures

Primary Outcome Measures :

1. Prostate cancer progression measured by PSA test [ Time Frame: At pre-study, and then every 3 months till 2 years, starting at week 7 for both arms ]
   Determine prostate cancer progression in patients receiving Proscavax vaccine (Arm 1) versus patients on active surveillance (Arm 2) by measuring change in PSA levels in patients in both arms
2. Prostate cancer progression measured by digital rectal examination (DRE) [ Time Frame: At pre-study and then every 6-months for 2 years ]
   Determine prostate cancer progression in patients receiving Proscavax vaccine (Arm 1) versus patients on active surveillance (Arm 2) by performing digital rectal examination (DRE) on patients in both arms
3. Prostate cancer progression measured by prostate Biopsy [ Time Frame: At pre-study and then every 12-months for 2 years ]
   Determine prostate cancer progression in patients receiving Proscavax vaccine (Arm 1) versus patients on active surveillance (Arm 2) by performing prostate biopsy on patients in both arms

Secondary Outcome Measures :

1. PSA doubling time [ Time Frame: At pre-study, and then every 3 months till 2 years, starting at week 7 for both arms ]
   Determine the time for the PSA level to double
2. Assessment of Adverse Events [ Time Frame: From first injection until 30 days past the 24-month assessments ]
   Confirm safety and tolerability of Proscavax vaccine

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Histologically confirmed adenocarcinoma of the prostate.
2. Age ≥ 18 years.

3. Clinically localized prostate cancer:

   • T1 (Cancer can only be seen under a microscope),
   • NX (Regional lymph nodes cannot be assessed) or N0 (Cancer cannot be seen in the lymph nodes),
   • MX (Presence of distant metastasis cannot be assessed) or M0 (Cancer hasn't spread to other parts of the body).
4. No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy).
5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.

6. Patients must have the following laboratory values:

   1. Absolute neutrophil count (ANC) > 1500/µL
   2. Platelet count >100,000/µL
   3. Hemoglobin > 10 g/dL
   4. Bilirubin < 1.5 x upper limits of normal
   5. Aspartate aminotransferase (AST) < 1.5 x upper limits of normal
   6. Adequate estimated glomerular filtration rate (eGFR) > 30 mL/min per 1.73 m2 (adjusted for race)
7. Patient consent has been obtained according to local Institutional Review Board for acquisition of research specimens.
8. Patient is accessible and compliant for follow-up.

9. Prostate biopsy requirements:

   1. If diagnosis was within one year of baseline visit, participant must have at least one biopsy with at least 10 cores.
   2. If diagnosis was more than 1 year prior to baseline visit, participant must have a minimum of 2 biopsies, one of which must be within 2 years prior to baseline visit. Patients must have been diagnosed with prostate cancer within 2 years of randomization (no history of prostate adenocarcinoma in any biopsies taken more than 2 years prior to randomization).

10. Must have NCCN low or favorable-intermediate risk prostate cancer defined as:

    • <50% of cores involved with cancer for eligibility and 50% or greater of cores involved with cancer progression. Only cores from standard TRUS biopsy (not MRI-guided cores) will be counted towards the number of cores involved.
    • No primary Gleason pattern 4 (Gleason score 4+3) disease in any cores (TRUS or MRI-guided)
    • PSA less than 20 ng/mL
    • No extracapsular extension (<T3)

11. Patients with female partners of childbearing potential must use at least one form of Investigator-approved contraception while on-study and for 30 days after their last administration of study investigational therapy. Acceptable birth control options include:

    1. surgical sterilization (patient and/or patient's partner),
    2. approved hormonal contraceptives or therapies (such as birth control pills, Depo-Provera, or Lupron Depot),
    3. barrier methods (such as a condom or diaphragm) used with a spermicide, and
    4. an intrauterine device (IUD).

Exclusion Criteria:

1. Unwillingness or inability (such as coagulopathy) to undergo serial prostate biopsy.
2. History of other malignancies, except: adequately treated non-melanoma skin cancer or adequately treated superficial bladder cancer (Ta) or other solid tumors curatively treated with no evidence of disease for > 5 years.
3. Evidence of metastatic prostate cancer.
4. Immune-compromised patients including but not limited to: systemic immune suppressive medications within 6 weeks of enrolling; HIV-positive and below normal cluster of differentiation 4 (CD4) lymphocytes (less than 500 cells per microliter). Patients must be tested for HIV seropositivity and CD4 lymphocyte count to be eligible for the study.
5. Inability to give consent.
6. Any condition that, according to the investigator, would make the patient an inappropriate study candidate.
7. Patients with significant cardiac disease including heart failure that meets New York Heart Association (NYHA) class II and IV definitions, history of myocardial infarction within 6 months of study entry, uncontrolled dysrhythmias.
8. Patients with existing autoimmune disorders (IL-2 and GM-CSF carry risk of exacerbating underlying autoimmune disorders).

Contacts and Locations

Contacts

Contact: Rupal S Bhatt, MD, PhD; (617) 735-2062; rbhatt@bidmc.harvard.edu

Locations

United States, Massachusetts

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215-5400

Contact: Rupal S Bhatt, MD, PhD

Principal Investigator: Rupal S Bhatt, MD, PhD

Sub-Investigator: Glen Bubley, MD

Sub-Investigator: David Einstein, MD

Dana Farber Cancer Institute

Boston, Massachusetts, United States, 02215

Contact: Lauren Harshman, MD

Principal Investigator: Lauren Harshman, MD

Sponsors and Collaborators

OncBioMune Pharmaceuticals

Investigators

• Principal Investigator: Rupal S Bhatt, MD, PhD; Harvard Medical Faculty Physicians Practice

More Information

• Responsible Party: OncBioMune Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT03579654
• Other Study ID Numbers: O17-11110
• First Posted: July 6, 2018
• Last Update Posted: March 6, 2019
• Last Verified: March 2019

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by OncBioMune Pharmaceuticals:

Prostate Specific Antigen; Immunotherapy

Additional relevant MeSH terms:

Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases